These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 14566766

  • 1. Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.
    Paret CL.
    J Ren Nutr; 2003 Oct; 13(4):288-94. PubMed ID: 14566766
    [Abstract] [Full Text] [Related]

  • 2. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D.
    J Nephrol; 2001 Oct; 14(3):176-83. PubMed ID: 11439741
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 7. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial.
    Chertow GM, Dillon MA, Amin N, Burke SK.
    J Ren Nutr; 2000 Jul; 10(3):125-32. PubMed ID: 10921533
    [Abstract] [Full Text] [Related]

  • 10. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR, Qunibi WY.
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB, Smeeding JE, Brook RA.
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [Abstract] [Full Text] [Related]

  • 16. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF.
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.